The PubMed entry documents a clinical trial titled Perioperative Apalutamide in High‑Risk Localized Prostate Cancer published in the New England Journal of Medicine. Citation details shown on the record include volume 395, issue 6, pages 546–560, DOI 10.1056/NEJMoa2603878, with an electronic publication date reported as May 31, 2026 and an indexed PubMed date of August 6, 2026. The article is designated as a Clinical Trial on the PubMed entry.
A link to the publisher’s full‑text options (Atypon/NEJM) is provided on the PubMed page. Beyond the bibliographic metadata and navigational elements, the supplied source content does not include the article abstract, methods, results, or authors’ conclusions.
The record lists a multi‑author group with Mary‑Ellen Taplin named first, followed by multiple academic and clinical coauthors including Martin Gleave, Neal D Shore, Angela Lopez‑Gitlitz, Alexander Kretschmer, Eleni Efstathiou, Paul L Nguyen, and others. Affiliations shown in the entry represent a mix of major academic cancer centers and clinical sites, for example Dana‑Farber Cancer Institute, University of British Columbia, Knight Cancer Institute at Oregon Health & Science University, Mass General Brigham/Harvard Medical School, Northwestern University Feinberg School of Medicine, and multiple international urology and oncology centers.
Industry contributions are indicated through authors affiliated with Johnson & Johnson and associated units. The PubMed display shows institutional affiliations for many named authors but does not include biographical or conflict‑of‑interest text in the supplied excerpt.
The article is associated with the corporate author group PROTEUS Investigators. The PubMed entry provides an extensive roster of collaborators and participating investigators across continents, including named investigators from North America, Europe, Asia, and Latin America. Several hundred individual contributors and a broad set of participating clinical sites are listed, reflecting a large, multicenter collaboration.
Affiliated institutions named in the entry include academic hospitals and cancer centers as well as community research sites. The list of collaborators and sites in the PubMed record demonstrates the trial’s multinational scope, but specific site‑level enrollment, country‑level participation numbers, or coordinating center details are not included in the provided content.
The PubMed record shows a link to Atypon (NEJM) for full‑text access, which is the standard publisher pathway for the New England Journal of Medicine. The supplied source body includes that link but does not reproduce the full article text or abstract content. Readers seeking the full protocol, methods, results, tables, figures, and authors’ discussion are directed to the NEJM full‑text link provided on the PubMed page.
From the content supplied here, the following items are explicitly reported:
Crucially, the supplied PubMed excerpt does not include the abstract, numerical results, statistical analyses, safety outcomes, perioperative management details, or the authors’ conclusions about the efficacy or harms of Apalutamide in the perioperative setting for High‑Risk Localized Prostate Cancer.
The PubMed page content provided here is limited to bibliographic and contributor information. Important clinical and methodological details necessary for interpretation and clinical application are not present in the supplied source text. Specifically absent from the excerpt are:
Because those elements were not included in the provided PubMed content, they cannot be summarized, restated, or interpreted here. To review the full trial methods and outcomes, consult the NEJM full‑text link indicated on the PubMed record or the official published article.